PT3609898T - Compostos úteis como inibidores de ret - Google Patents

Compostos úteis como inibidores de ret

Info

Publication number
PT3609898T
PT3609898T PT187192760T PT18719276T PT3609898T PT 3609898 T PT3609898 T PT 3609898T PT 187192760 T PT187192760 T PT 187192760T PT 18719276 T PT18719276 T PT 18719276T PT 3609898 T PT3609898 T PT 3609898T
Authority
PT
Portugal
Prior art keywords
compounds useful
ret inhibitors
ret
inhibitors
compounds
Prior art date
Application number
PT187192760T
Other languages
English (en)
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of PT3609898T publication Critical patent/PT3609898T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
PT187192760T 2017-04-13 2018-04-13 Compostos úteis como inibidores de ret PT3609898T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1705971.8A GB201705971D0 (en) 2017-04-13 2017-04-13 Inhibitor compounds

Publications (1)

Publication Number Publication Date
PT3609898T true PT3609898T (pt) 2022-08-25

Family

ID=58744532

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187192760T PT3609898T (pt) 2017-04-13 2018-04-13 Compostos úteis como inibidores de ret

Country Status (19)

Country Link
US (2) US11352361B2 (pt)
EP (2) EP3609898B1 (pt)
JP (2) JP7277376B2 (pt)
CN (2) CN115785100A (pt)
AU (2) AU2018252251B2 (pt)
BR (1) BR112019021231A2 (pt)
CA (1) CA3059134A1 (pt)
DK (1) DK3609898T3 (pt)
ES (1) ES2925077T3 (pt)
GB (1) GB201705971D0 (pt)
HR (1) HRP20221040T1 (pt)
HU (1) HUE059716T2 (pt)
LT (1) LT3609898T (pt)
PL (1) PL3609898T3 (pt)
PT (1) PT3609898T (pt)
RS (1) RS63514B1 (pt)
RU (1) RU2760669C2 (pt)
SI (1) SI3609898T1 (pt)
WO (1) WO2018189553A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231681T1 (hr) 2015-11-02 2024-04-12 Blueprint Medicines Corporation Inhibitori za ret
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
JP7061195B2 (ja) * 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
MX2020010417A (es) 2018-04-03 2021-01-08 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
JP2021534129A (ja) 2018-08-10 2021-12-09 ブループリント メディシンズ コーポレイション Ｅｇｆｒ変異がんの処置
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
EP3950685A4 (en) * 2019-04-03 2022-12-14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory PYRAZOLOPYRIDINE COMPOUND USED AS RET INHIBITOR AND USES THEREOF
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
US20230365596A1 (en) * 2020-09-29 2023-11-16 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Crystal forms of pyridopyrazole compounds and preparation method therefor
US20230039586A1 (en) * 2021-07-12 2023-02-09 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
WO2023064843A1 (en) * 2021-10-15 2023-04-20 Stemline Therapeutics, Inc. Inhibitors of mutant ret kinases for use in treating cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1154774B1 (en) 1999-02-10 2005-06-22 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
PT1951724E (pt) 2005-11-17 2011-08-02 Osi Pharm Inc Inibidores mtor fundidos bicíclicos
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US20080299113A1 (en) * 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
JP5512975B2 (ja) * 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
US20090274698A1 (en) 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
RU2513636C2 (ru) * 2008-01-04 2014-04-20 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
MX352661B (es) * 2009-11-05 2017-12-04 Rhizen Pharmaceuticals S A Star Moduladores novedosos de benzopiran cinasa.
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
EP2528919B1 (en) 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20110304649A1 (en) * 2010-06-10 2011-12-15 Microsoft Corporation Character selection
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
CN103703174B (zh) 2011-05-04 2017-05-10 因特利凯有限责任公司 联合药物组合物及其用途
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
WO2013070976A1 (en) 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
JP6397897B2 (ja) * 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
ES2792036T3 (es) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
CA2974702C (en) 2015-01-26 2023-10-10 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
KR101766194B1 (ko) * 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
DK3442535T3 (da) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Heterocykliske stoffer som as ret-kinase-hæmmere
KR102390578B1 (ko) 2016-04-15 2022-04-26 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
RS63514B1 (sr) 2022-09-30
ES2925077T3 (es) 2022-10-13
WO2018189553A1 (en) 2018-10-18
RU2019132155A3 (pt) 2021-05-13
EP3609898B1 (en) 2022-06-01
SI3609898T1 (sl) 2022-11-30
AU2018252251A1 (en) 2019-10-17
CN110506043B (zh) 2022-11-01
JP2023103326A (ja) 2023-07-26
US20200157107A1 (en) 2020-05-21
EP3609898A1 (en) 2020-02-19
HRP20221040T1 (hr) 2022-11-11
EP4105219A1 (en) 2022-12-21
RU2760669C2 (ru) 2021-11-29
RU2019132155A (ru) 2021-05-13
PL3609898T3 (pl) 2022-09-26
AU2018252251B2 (en) 2022-03-31
DK3609898T3 (da) 2022-09-05
CN115785100A (zh) 2023-03-14
US20220348585A1 (en) 2022-11-03
JP7277376B2 (ja) 2023-05-18
HUE059716T2 (hu) 2022-12-28
LT3609898T (lt) 2022-09-12
CN110506043A (zh) 2019-11-26
JP2020516636A (ja) 2020-06-11
BR112019021231A2 (pt) 2020-04-28
US11680068B2 (en) 2023-06-20
US11352361B2 (en) 2022-06-07
GB201705971D0 (en) 2017-05-31
CA3059134A1 (en) 2018-10-18
AU2022202325A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HUE059716T2 (hu) RET inhibitorként jól használható vegyületek
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
ZA201708244B (en) Thioether compounds as nitrification inhibitors
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
IL274821A (en) Substances that inhibit MPGES-1 and their uses
PL3589637T3 (pl) Związki użyteczne do hamowania ror-gamma-t
SI3589638T1 (sl) Spojine uporabne pri inhibiciji ROR-GAMMA-T
GB201720145D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
GB201522245D0 (en) Compounds useful as kinase inhibitors